17:47 , Mar 23, 2018 |  BC Week In Review  |  Company News

Regeneron IDs gene variant tied to NASH, partners with Alnylam

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) partnered with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to develop RNAi therapeutics that target the hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) gene to treat non-alcoholic steatohepatitis. In a paper published March 21 in the...
23:38 , Mar 21, 2018 |  BC Extra  |  Company News

Regeneron IDs gene variant tied to NASH, partners with Alnylam

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) partnered with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to develop RNAi therapeutics that target the hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) gene to treat non-alcoholic steatohepatitis. In a paper published Wednesday in the New...